RxDoctor Payments Data

Rahel Dagne, MD

Hospitalist · Fredericksburg, VANPI 1073931937

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $261, 4.7 times the $55 reported in 2019. Among hospitalist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$985in general payments, 2019–2025

Across 45 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$153
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$132
  • AstraZeneca$109
  • Madrigal Pharmaceuticals$101
  • Johnson & Johnson$77
  • Paratek Pharmaceuticals, Inc.$52
  • plus $361 from 15 others

What the payments were for

  • Food & beverage$985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$985 in reported general payments places this provider in the 95th percentile of 539 hospitalist providers in Virginia.

See all hospitalist providers in Virginia

Medicare billing

Part B allowed, 2024
$111,955
Medicare patients
446
Services billed
1,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$7,041
Nitroglycerin13$241
Cefdinir34$204
Pantoprazole Sodium31$155
Quetiapine Fumarate15$140
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$139
Metronidazole13$122
Prednisone19$85
Hydralazine Hcl14$78
Losartan Potassium18$68
Furosemide30$67
Atorvastatin Calcium12$60
Carvedilol13$36
Amlodipine Besylate12$31
Metoprolol Tartrate11$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$7,04112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 539 hospitalist providers in Virginia.

Other hospitalist in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →